ProfileJobs (8)

Cancer Genetics

Healthgeneticsmedical diagnosticsoncology

Cancer Genetics, Inc. (CGI) provides DNA-based cancer diagnostics and services to medical institutions. The Company's tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services. CGI’s tests and reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. The Company's reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited.

Company Growth (employees)
Type
Public
HQ
Rutherford, US
Founded
1999
Size (employees)
142 (est)-36%
Website
cancergenetics.com
Cancer Genetics was founded in 1999 and is headquartered in Rutherford, US

Key People at Cancer Genetics

Panna Sharma

Panna Sharma

President & CEO

Cancer Genetics Office Locations

Cancer Genetics has offices in Rutherford, Morrisville, Los Angeles, Shanghai and in 1 other location
Rutherford, US (HQ)
Complex 201 Route 17 North
Shanghai, CN
Zhong Guo Yi Dong （ Cai Lun Lu ）
Los Angeles, US
Health Research Association 1640 Marengo St
Morrisville, US
133 Southcenter Ct

Cancer Genetics Data and Metrics

Cancer Genetics Financial Metrics

Cancer Genetics's revenue was reported to be $7 m in Q1, 2017
USD

Revenue (Q1, 2017)

7 m

Gross profit (Q1, 2017)

2.8 m

Gross profit margin (Q1, 2017), %

40%

EBIT (Q1, 2017)

(2.8 m)

Market capitalization (21-Jul-2017)

72.8 m

Cash (31-Mar-2017)

9.7 m
Cancer Genetics's current market capitalization is $72.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

6.6 m10.2 m18 m27 m

Revenue growth, %

54%77%50%

Cost of goods sold

4.9 m8.5 m14.1 m17.1 m

Gross profit

1.7 m1.7 m3.9 m9.9 m

Gross profit Margin, %

25%17%22%37%

Sales and marketing expense

4.7 m

R&D expense

6 m

General and administrative expense

16 m

Operating expense total

10.1 m21 m25.3 m26.7 m

EBIT

(8.4 m)(18.3 m)(20.7 m)(16.7 m)

EBIT margin, %

(128%)(179%)(115%)(62%)

Interest expense

(2.4 m)(472.8 k)(344 k)(454 k)

Interest income

29.7 k73.8 k49 k23 k

Pre tax profit

(13 m)(19 m)(21.4 m)(15.8 m)

Income tax expense

(663.9 k)(2.4 m)

Net Income

(12.4 m)(16.6 m)(20.2 m)(15.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.5 m3.2 m4.4 m4.2 m4 m6.1 m7 m6.8 b7 m

Cost of goods sold

1.5 m2.6 m3.1 m3.1 m3.1 m4.1 m4.3 m4.4 b4.2 m

Gross profit

8.6 k656.1 k1.2 m1.1 m897.1 k2 m2.7 m2.3 b2.8 m

Gross profit Margin, %

1%20%28%26%22%32%39%34%40%

Sales and marketing expense

918.5 k1.1 m1.1 m1.2 m1.2 m1.3 m1.4 m1.1 b971 k

R&D expense

1.1 m1.4 m1.3 m1.3 m1.8 m1.5 m1.7 m1.6 b1.1 m

General and administrative expense

2.4 m3.1 m3 m3.1 m3.5 m4.3 m3.7 m3.7 b3.5 m

Operating expense total

4.4 m5.6 m5.4 m5.5 m6.5 m7.1 m6.7 m6.3 b5.6 m

EBIT

(4.4 m)(4.9 m)(4.2 m)(4.4 m)(5.6 m)(5.2 m)(4 m)(4 b)(2.8 m)

EBIT margin, %

(292%)(152%)(95%)(105%)(141%)(85%)(57%)(60%)(40%)

Interest expense

(30.7 k)(36.2 k)(34 k)(81.6 k)(111.6 k)(126 k)(107 k)(111 m)(194 k)

Interest income

16.2 k18.8 k12.6 k12.8 k4.9 k4 k13 k4 m17 k

Pre tax profit

(4.2 m)(4.8 m)(4.3 m)(5 m)(5.2 m)(10.6 m)

Net Income

(6.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

49.5 m25.6 m19.5 m9.5 m

Current Assets

51.9 m31.8 m28.2 m23.4 m

PP&E

1.3 m4.4 m6.1 m4.7 m

Goodwill

3 m12 m12 m

Total Assets

55.2 m47.1 m48.9 m42.4 m

Accounts Payable

2.3 m3.8 m7.6 m8.1 m

Current Liabilities

8.6 m4.4 m9.9 m11 m

Total Liabilities

16.8 m

Additional Paid-in Capital

106.8 m112.5 m131.2 m139.6 m

Retained Earnings

(61.3 m)(98.2 m)(114 m)

Total Equity

45.5 m33 m25.6 m

Financial Leverage

1.2 x1.5 x1.7 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

23.7 m19.9 m13.3 m10.6 m10.7 m9.7 m

Current Assets

31.1 m3.8 m23.5 m24.5 m26.6 m24.4 m

PP&E

3.9 m5.9 m5.4 m4.9 m4.8 m

Goodwill

3.2 m3.2 m12 m12 m12 m12 m

Total Assets

39.8 m36 m44 m44.2 m45.8 m43.4 m

Accounts Payable

4.1 m4.4 m7.8 m7.6 m8.3 m8.1 m

Current Liabilities

4.8 m6.5 m10.3 m10.1 m10.6 m8.8 m

Additional Paid-in Capital

114 m114.8 m131.7 m136.6 m139 m144.5 m

Total Equity

26.8 m22.3 m28.3 m29.2 m27.8 m20.9 m

Financial Leverage

1.5 x1.6 x1.6 x1.5 x1.6 x2.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(12.4 m)(16.6 m)(20.2 m)(15.8 m)

Depreciation and Amortization

311.2 k810.2 k1.5 m2 m

Accounts Receivable

(716.5 k)(1.7 m)(1.7 m)(5.9 m)

Cash From Operating Activities

48.6 m(23.9 m)(6.1 m)

Purchases of PP&E

(257.3 k)(1.4 m)(1 m)(490 k)

Cash From Investing Activities

(1.4 m)(11.4 m)(2.6 m)(609 k)

Short-term Borrowings

(3.6 m)(408.4 k)(1.3 m)

Cash From Financing Activities

58.1 m10.1 m8.5 m

Interest Paid

608.1 k128.4 k240 k333 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(6.7 m)

Depreciation and Amortization

214.5 k487.7 k347.7 k679.6 k971.2 k518 k1 m1.5 m534 k

Accounts Receivable

(489.2 k)(521.4 k)(17.2 k)(909.9 k)(349.4 k)(1.8 m)(5.3 m)(7.1 m)(901 k)

Purchases of PP&E

(385.2 k)(944.4 k)(83.1 k)(257.5 k)(439.7 k)(319 k)(319 k)(345 k)(178 k)

Cash From Investing Activities

(6.4 m)(10.9 m)(123.2 k)5.7 m4.6 m(358 k)(405 k)(472 k)(209 k)

Short-term Borrowings

(22.3 k)(127.5 k)

Cash From Financing Activities

218.9 k108 k(124.9 k)(257.3 k)4.1 m9 m2.8 m

Interest Paid

61.4 k92.7 k33.9 k72.3 k157.6 k97 k202 k250 k269 k
USDY, 2017

Revenue/Employee

38.2 k

Financial Leverage

2.1 x

Cancer Genetics Market Value History

Market Position of Cancer Genetics

Competitors

Genomic Health
Health - Public
Lineagen
Health - Private
Natera
Health - Public
Myriad Genetics
Health - Public
Compare competitors

Cancer Genetics Online and Social Media Presence

Cancer Genetics Company Life and Culture

You may also be interested in